DERMATOLOGY / CLINICAL RESEARCH
Serum γ-Klotho and fibroblast growth factor-2 levels in patients with pressure ulcers
More details
Hide details
1
Department of Family Medicine, Sultangazi Haseki Training and Research Hospital, Istanbul, Turkey
2
Department of Internal Medicine, Sultangazi Haseki Training and Research Hospital, Istanbul, Turkey
3
Department of Family Medicine, Health Science University, Kartal Dr. Lutfi Kırdar City Hospital, Istanbul, Turkey
4
Department of Medical Biochemistry, Sultangazi Haseki Training and Research Hospital, Istanbul, Turkey
Submission date: 2025-05-28
Final revision date: 2025-07-09
Acceptance date: 2025-08-03
Online publication date: 2025-10-05
Corresponding author
Sabah Tuzun
Department of
Family Medicine
Haseki Sultangazi Training
and Research Hospital
Uğur Mumcu Province
No. 7, Belediye Road
Sultangazi, Istanbul, Turkey
Phone: +90 2124532000
KEYWORDS
TOPICS
ABSTRACT
Introduction:
This study aimed to evaluate the serum levels of -Klotho and fibroblast growth factor 2 (FGF2) in patients with pressure ulcers.
Material and methods:
Patients aged ≥ 18 years receiving care from Home Health Care Services were included. The case group consisted of individuals with stage 2–4 pressure ulcers, while the control group comprised patients without ulcers, matched for age and sex. Sociodemographic characteristics, medical device usage, and nutritional status were assessed for all participants. In the case group, additional data regarding ulcer site, stage, number, and dimensions were collected. Serum levels of -Klotho and FGF2 were measured using ELISA.
Results:
A total of 80 participants were enrolled (40 (50.0%) in each group). The median FGF2 level was 220.8 [IQR 26.8] pg/ml in the case group and 219.1 [29.1] pg/ml in the control group (p = 0.577). Similarly, the median -Klotho level was 1448.4 [158.6] pg/ml in the case group and 1421.3 [232.8] pg/ml in the control group (p = 0.453). Additionally, a significant correlation was observed between -Klotho and FGF2 levels in the case group (p = 0.048), whereas no such association was found in the control group (p = 0.164). Furthermore, FGF2 levels were positively associated with the number, width, and length of the wounds (p = 0.003, p = 0.007, and p = 0.012, respectively), while a negative correlation was observed between -Klotho levels and wound duration (p = 0.026).
Conclusions:
Although serum levels did not differ between groups, the exclusive correlation between -Klotho and FGF2 in the pressure ulcer group suggests a potential association with chronic wound characteristics, warranting further investigation.
REFERENCES (18)
1.
Anders J, Heinemann A, Leffmann C, Leutenegger M, Pröfener F, von Renteln-Kruse W. Decubitus ulcers: pathophysiology and primary prevention. Dtsch Arztebl Int 2010; 107: 371-82.
2.
Yamauchi M, Hirohashi Y, Torigoe T, et al. Wound healing delays in a-Klotho-deficient mice that have skin appearance similar to that in aged humans e Study of delayed wound healing mechanism. Biochem Biophys Res Commun 2016; 473: 845-52.
3.
Laiva AL, O’Brien FJ, Keogh MB. Anti-aging-Klotho gene-activated scaffold promotes rejuvenative wound healing response in human adipose-derived stem cells. Pharmaceuticals 2021; 14: 1168.
4.
Koike Y, Yozaki M, Utani A, Murota H. Fibroblast growth factor 2 accelerates the epithelial–mesenchymal transition in keratinocytes during wound healing process. Sci Rep 2020; 10: 18545.
5.
Liu Y, Liu Y, Deng J, Li W, Xuqiang N. Fibroblast growth factor in diabetic foot ulcer: progress and therapeutic prospects. Front Endocrinol 2021; 12: 744868.
6.
Farooq M, Khan AW, Kim MS, Choi S. The role of fibroblast growth factor (FGF) signaling in tissue repair and regeneration. Cells 2021; 10: 3242.
7.
Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. WIREs Mech Dis 2022; 14: e1549.
8.
Petit I, Levy A, Estrach S, et al. Fibroblast growth factor 2 bound to specific dermal fibroblast derived extracellular vesicles is protected from degradation. Sci Rep 2022; 12: 22131.
9.
Syromiatnikova VY, Kvon AI, Starostina IG, Gomzikova MO. Strategies to enhance the efficacy of FGF2-based therapies for skin wound healing. Arch Dermatol Res 2024; 316: 405.
10.
Zhang J, Liu Z, Li Y, et al. FGF2: a key regulator augmenting tendon-to-bone healing and cartilage repair. Regen Med 2020; 15: 2129-42.
11.
Sun F, Liang P, Wang B, Liu W. The fibroblast growth factor–Klotho axis at molecular level. Open Life Sci 2023; 18: 20220655.
12.
Hajare AD, Dagar N, Gaikwad AB. Klotho antiaging protein: molecular mechanisms and therapeutic potential in diseases. Mol Biomed 2025; 6: 19.
13.
Scazzone C, Agnello L, Runa Lo Sasso BL, et al. Klotho and vitamin D in multiple sclerosis: an Italian study. Arch Med Sci 2020; 16: 842-7.
14.
Liu J, Shi D, Song X, Ji Y. Soluble -klotho as a potential predictor of all-cause mortality in Chinese maintenance hemodialysis patients. Arch Med Sci 2022. DOI:
https://doi.org/10.5114/aoms/1....
15.
Tyurenkov IN, Perfilova VN, Nesterova AA, Glinka Y. Klotho protein and CardioVascular System. Biochemistry 2021; 86: 132-45.
16.
El-Saeed WS, Elnagdy MH, Abd elghaffar MA, Elbaz A, Zahran MA. Role of alpha and gamma Klotho genes in the development of differentiated thyroid carcinoma on top of goiter. FCO 2023; 13: 31-9.
17.
Buchanan S, Combet E, Stenvinkel P, Shiels PG. Klotho, aging, and the failing kidney. Front Endocrinol 2020; 11: 560.
18.
Li X, Wang C, Xiao J, McKeehan WL, Wang F. Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol 2016; 53: 155-67.